BRIEF-Agomab Announces First Patient Dosed In Global Nov-Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Reuters2026/10/13 20:14Agomab Therapeutics NV AGMB.O:
AGOMAB ANNOUNCES FIRST PATIENT DOSED IN GLOBAL NOV-ERA PHASE 2B STUDY OF ONTUNISERTIB IN FIBROSTENOSING CROHN'S DISEASE
AGOMAB THERAPEUTICS NV - NOV-ERA PHASE 2B STUDY EXPECTED TO ENROLL ABOUT 320 PATIENTS GLOBALLY
Source text: ID:nGNX31Vcl9
Further company coverage: AGMB.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cathie Wood Blames Anthropic’s CEO for AI Panic: Why Attack a Company Her Fund Backs?
Anthropic's $1.5 Trillion IPO: What Investors Should Know Before Buying
Why is the US Dollar Falling? Midterms, Yields, and a Critical Economic Test
Bitcoin and Nvidia are Losing to Restaurant Chain Stocks in 2026
Crypto prices
More
